Case-control study of diabetes mellitus in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue 4, 2004, Pages 1464-1469

  Yoon, Cecilia ^a,c   Gulick, Roy M ^a   Hoover, Donald R ^b   Vaamonde, Carlos M ^a   Glesby, Marshall J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Center for Special Studies   (United States)

Author keywords

Diabetes mellitus; Hepatitis C virus; Hyperglycemia; Metabolic complications of HIV infection; Risk factors

Indexed keywords

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; CASE-CONTROL STUDIES; COMORBIDITY; DIABETES MELLITUS; FAMILY HEALTH; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 10044231525     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000137373.26438.18     Document Type: Article

References (42)

1. Dube MP, Johnson DL, Currier JS, et al. Protease inhibitor associated hyperglycemia. Lancet. 1997;350:713-714.
2. Dever LL, Oruwari PA, Figueroa WE, et al. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother. 2000;34:580-584.
3. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus; a cohort study. Lancet. 1999;353:2093-2099.
4. Currier J, Boyd F, Kawabata H, et al. Diabetes mellitus in HIV infected individuals [abstract 677-T]. Presented at the 9th Conference on Retrovirus and Opportunistic Infections, Seattle, February 2002.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter of less. N Engl J Med. 1997;337:725-732.
6. Vigouroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab. 1999;25:225-232.
7. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000;31:1467-1475.
8. Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother. 2001;35:343-351.
9. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298-302.
10. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15(Suppl):F11-F18.
11. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis. 2000;30(Suppl 2):S135-S142.
12. van der Valk M, Bisschop PH, Romijn JA, et al. Lipodystrophy in HIV-1 positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15:2093-2100.
13. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab. 2001;12:413-419.
14. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139.
15. Palacios R, Santos J, Ruiz J, et al. Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: a case-control study. AIDS. 2003;17:933-935.
16. American Diabetes Association. Supplement 1. Screening for type 2 diabetes. Diabetes Care. 2000;23(Suppl 1):S20-S23.
17. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592-599.
18. Mason AL, Lau JYN, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328-333.
19. Garrido A, Guerrero FJ, Lepe JA, et al. Hepatitis C and diabetes mellitus: what is the connection? Presented at the 37th Annual Meeting of European Association for the Study of the Liver; Madrid, April 2002.
20. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis. 2003;36:1318-1323.
21. Kilby JM, Tabereaux PB. Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:46-50.
22. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16(Suppl):F1-F8.
23. Nolte LA, Yarasheski KE, Kawanaka K, et al. The HIV protease inhibitor indinavir decreases insulin-and contraction-stimulated glucose transport in skeletal muscle. Diabetes. 2001;50:1397-1401.
24. Murata H, Hruz PW, Mueekler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS. 2002;16:859-863.
25. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis. 2000;31:1482-1487.
26. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr. 2000;25:312-321.
27. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1999;84:1932-1937.
28. Hadigan C, Corcoran C, Stanley T, et al. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab. 2000;85:35-41.
29. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:245-250.
30. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
31. Sutinen J, Hakkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS. 2002;16:2183-2193.
32. Chung RT, Casson DR, Murray G, et al. Alanine aminotransferase levels predict insulin resistance in HIV lipodystrophy. J Acquir Immune Defic Syndr. 2003;34:534-536.
33. Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1993;17:117-119.
34. Marcellin P, Martinot-Peignoux M, Elias A, et al. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis. 1994;170:433-435.
35. Best JD, O'Neal DN. Diabetic dyslipidaemia: current treatment recommendations. Drugs. 2000;59:1101-1111.
36. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed pre-diabetic individuals. Does the clock start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
37. Mykkanen L, Kuusisto J, Pyorala K, et al. Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia. 1993;36:553-559.
38. Defronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318-368.
39. Reeds DN, Mittendorfer B, Patterson BW, et al. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab. 2003;285(Suppl):E490-E497.
40. Meininger G, Hadigan C, Laposata M, et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism. 2002;51:260-266.
41. Poles MA, Dieterich DT. Hepatitis C virus/human immunodeficiency virus coinfection: clinical management issues. Clin Infect Dis. 2000;31:154-161.
42. Sulkowski MS, Mast EE, Seeff LB, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl):S77-S84.